Company code: Wuxi Apptec Co.Ltd(603259) company abbreviation: Wuxi Apptec Co.Ltd(603259) Wuxi Apptec Co.Ltd(603259)
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 All directors of the company attended the board meeting. 3、 Deloitte Touche Tohmatsu (special general partnership) has issued a standard unqualified audit report for the company. 4、 The person in charge of accounting (Li Jin, GE) and the person in charge of financial reporting of the company: Li Jin, the person in charge of accounting (GE) and the person in charge of financial reporting of the company. 5、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The company’s profit distribution plan for 2021: Based on the total share capital on the equity registration date of profit distribution in 2021, a cash dividend of RMB 5.1740 (including tax) will be distributed for every 10 shares (based on the current total share capital of the company, a total of RMB 152930614792 (including tax)). If the total share capital of the company changes before the equity registration date of equity distribution, it will be distributed according to the principle that the distribution amount per share remains unchanged, and the total distribution amount will be adjusted accordingly. 6、 Risk statement of forward-looking statements √ applicable □ not applicable
The future plans, development strategies and other forward-looking descriptions involved in this report do not constitute the company’s commitment to investors. Please pay attention to investment risks. 7、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties? VIII. Whether there is any external guarantee in violation of the specified decision-making procedures? IX. whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? X. major risk tips
During the reporting period, there were no particularly significant risks that had a material impact on the company’s production and operation. The company has described in detail the relevant risks that may be faced in the process of production and operation in this report. For details, see the relevant contents in Section III, VI and (IV) “possible risks” of this report. 11、 Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 35 Section V environmental and social responsibility 62 section VI important matters Section VII changes in shares and shareholders 101 Section VIII preferred shares 116 section IX relevant information of bonds 117 section x financial reporting one hundred and twenty-one
Financial statements containing the signatures and seals of the legal representative of the company, the person in charge of accounting work and the person in charge of accounting organization
The original of the audit report with the seal of the accounting firm and the signature and seal of the certified public accountant
The list of documents for future reference contains the annual report and summary documents signed by the legal representative of the company and sealed by the company
Written confirmation of this annual report signed by directors, supervisors and senior managers
The board of directors deliberated and adopted the resolution of this annual report
The board of supervisors deliberated and adopted the resolution of this annual report
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company, the company and Wuxi Apptec Co.Ltd(603259) refer to Wuxi Apptec Co.Ltd(603259)
The group refers to Wuxi Apptec Co.Ltd(603259) and its subsidiaries
The articles of association refers to the Wuxi Apptec Co.Ltd(603259) articles of association
The reporting period and the current reporting period refer to January December 2021
The end of the reporting period refers to the end of December 31, 2021
Yaoming Co., Ltd. refers to Wuxi Yaoming Kant new drug development Co., Ltd., the predecessor of Wuxi Apptec Co.Ltd(603259) company
Shanghai Yaoming / Shanghai Wuxi Apptec Co.Ltd(603259) refers to Shanghai Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Suzhou Yaoming refers to Suzhou Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Hequan pharmaceutical refers to Shanghai Hequan Pharmaceutical Co., Ltd
Tianjin Yaoming refers to Tianjin Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Wuhan Yaoming refers to Wuhan Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Nantong Yaoming refers to Nantong Wuxi Apptec Co.Ltd(603259) Pharmaceutical Technology Co., Ltd
Yaoming union refers to Wuxi Xdc (Cayman) Inc
Yaoming biology refers to Wuxi Biology (Cayman) Inc
Changzhou Hequan refers to Changzhou Hequan Pharmaceutical Co., Ltd
Huiyuan biotechnology refers to Huiyuan Biotechnology (Shanghai) Co., Ltd
The State Drug Administration refers to the State Drug Administration. If necessary, including its predecessor, the State Food and Drug Administration of the people’s Republic of China
CSRC refers to the China Securities Regulatory Commission
Shanghai stock exchange refers to Shanghai Stock Exchange
SEHK / SEHK means the stock exchange of Hong Kong Limited
Yuan, ten thousand yuan and one hundred million yuan refer to RMB, ten thousand yuan and one hundred million yuan
Shares refer to ordinary shares with a par value of RMB 1.00 per share in the share capital of the company, including A-Shares and H shares
Clinical research is a part of medical research and health research. Its purpose is to establish the basic theory of human disease mechanism, disease prevention and health promotion.
Clinical research involves the study of doctor-patient interaction and diagnostic clinical data, data or patient group data
Pharmaceutical R & D services refer to cro and cdmo businesses in this report
Small molecule drugs refer to small molecule drugs, mainly chemical synthetic drugs, with a molecular weight of less than 1000 daltons. They have the advantages of wide use and mature theory. At present, the vast majority of mature drugs in the market are small molecule drugs
Lead compound refers to a compound with pharmacological or biological activity, which can be used to develop new drugs, and its chemical structure can be further optimized to improve drug potency, selectivity and pharmacokinetic properties. Lead compounds can be found by high-throughput screening or by secondary metabolites of natural substances
Innovative drugs refer to a class of chemical drugs classified according to the registration classification standard of chemical drugs of the State Food and drug administration, and a class of biological products classified according to the registration classification of biological products of the State Food and drug administration
API refers to active pharmaceutical ingredients, also known as active pharmaceutical ingredients, which are prepared by chemical synthesis, plant extraction or biotechnology, but can not be taken directly by patients. Generally, they are added with excipients and processed,
Preparation for direct use
Clinical trial refers to any systematic study of drugs in human body (patients or healthy volunteers) to confirm or reveal the effects and adverse reactions of test drugs and / or the absorption, distribution, metabolism and excretion of test drugs, with the purpose of determining the efficacy and safety of test drugs
Precision medicine refers to a new medical concept and medical model based on individualized medicine and developed with the rapid progress of genome sequencing technology and the cross application of biological information and big data science. Its essence is through genomic, proteome and other genomic technologies and medical frontier technologies, Analyze, identify, verify and apply biomarkers for large sample population and specific disease types, so as to accurately find the cause of the disease and the target of treatment, and accurately classify the different states and processes of a disease, Finally, it is a treatment mode to realize the purpose of personalized and accurate treatment for diseases and specific patients and improve the benefits of disease diagnosis, treatment and prevention
The new leasing standards refer to the accounting standards for Business Enterprises No. 21 – leasing
Convertible bonds refer to the zero interest convertible bonds of USD 300 million issued by Wuxi Apptec Co.Ltd(603259) on September 17, 2019 and maturing in 2024
2018 incentive plan refers to Wuxi Apptec Co.Ltd(603259) 2018 restricted stock and stock option incentive plan
2019 incentive plan refers to Wuxi Apptec Co.Ltd(603259) 2019 restricted stock and stock option incentive plan
Zhongdeng Shanghai branch refers to the Shanghai Branch of China Securities Depository and Clearing Co., Ltd
Apptec means Wuxi apptec, Inc
ADC refers to antibody drug conjugate
AAALAC means AAALAC international, International Committee for the evaluation and Accreditation of laboratory animals
Crelux means crelux
